person · Reporting owner
Yeleswaram Krishnaswamy
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Chief Development Officer | August 24, 2026 | August 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rapport Therapeutics, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 195,862 |
Ending reported balance
After 2026-08-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-08-24 · Sale · Disposed 13,160 · Balance 232,862 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 2 · 2026-08-25 · Sale · Disposed 20,799 · Balance 212,063 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 3 · 2026-08-25 · Sale · Disposed 16,201 · Balance 195,862 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2026 Filed Aug 26, 2026 20:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 16,201 | $51.06 | $827,184.18 |
DisclosureSEC source: 0001193125-26-368244 · ownership.xml · nonDerivative · entry 3 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,862 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 25, 2026 Filed Aug 26, 2026 20:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 20,799 | $50.31 | $1,046,420.57 |
DisclosureSEC source: 0001193125-26-368244 · ownership.xml · nonDerivative · entry 2 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 212,063 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 24, 2026 Filed Aug 26, 2026 20:00 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 13,160 | $50.00 | $657,977.63 |
DisclosureSEC source: 0001193125-26-368244 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,862 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| August 19, 2026 Filed Aug 20, 2026 20:09 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 404 | $49.90 | $20,159.60 |
DisclosureSEC source: 0001193125-26-359189 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,022 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Read SEC document |
| April 17, 2026 Filed Apr 21, 2026 20:55 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 20,225 | $39.99 | $808,844.27 |
DisclosureSEC source: 0001193125-26-167091 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 246,426 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 14, 2026 Filed Apr 14, 2026 20:13 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 10,200 | $35.08 | $357,796.62 |
DisclosureSEC source: 0001193125-26-154908 · ownership.xml · nonDerivative · entry 3 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 266,651 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 13, 2026 Filed Apr 14, 2026 20:13 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 9,165 | $34.97 | $320,536.71 |
DisclosureSEC source: 0001193125-26-154908 · ownership.xml · nonDerivative · entry 2 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 276,851 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| April 10, 2026 Filed Apr 14, 2026 20:13 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 500 | $34.98 | $17,490.00 |
DisclosureSEC source: 0001193125-26-154908 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,016 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Read SEC document |
| April 08, 2026 Filed Apr 9, 2026 20:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 360 | $34.90 | $12,564.00 |
DisclosureSEC source: 0001193125-26-149725 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,516 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Read SEC document |
| March 25, 2026 Filed Mar 26, 2026 20:41 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 10,115 | $29.99 | $303,354.92 |
DisclosureSEC source: 0001193125-26-126410 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 286,876 F1 · kind: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:11 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001193125-26-037581 · ownership.xml · derivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-02-02 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:19 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | SaleCommon Stock | 2,840 | $30.05 | $85,342.00 |
DisclosureSEC source: 0001193125-26-002469 · ownership.xml · nonDerivative · entry 2 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 296,991 F2 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:19 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantCommon Stock | 9,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-002469 · ownership.xml · nonDerivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,831 F1 · kind: On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025. F1 · price: On December 4, 2024, the Reporting Person was granted performance-based restricted stock units ("PSUs") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:30 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $16.60 | $0.00 |
DisclosureSEC source: 0000950170-25-013753 · ownership.xml · derivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2035-02-03 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 23:42 UTC | Rapport Therapeutics, Inc. RAPP · Entity 4394 | GrantStock Option (Right to Buy) · Derivative | 84,904 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000950170-24-071538 · ownership.xml · derivative · entry 1 Yeleswaram Krishnaswamy · CIK 0002022156 · Chief Development Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,904 Underlying: Common Stock · 84,904 shares Expires 2034-06-05 F1 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on June 6, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.